You can choose from these two topics:
1. the modes of action of immune checkpoint inhibitors such as nivolumab and ipilimumab, with particular attention to interactions with the intestinal microbiome
2. the evolving therapeutic options for oestrogen-driven breast cancer and the intersection between metabolic disorders and breast cancer progression
